CMV reactivation after autologous stem cell transplantation: exploratory associations with transfusion burden and pre-transplant IMID exposure
Journal of Current Hematology & Oncology Research · 13.11.2026 · 4 (4) · 135-139
DOI: 10.51271/jchor-0097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Current Hematology & Oncology Research, online erschienen am 13.11.2026. Verfasst von Meral Ilgaz und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
To evaluate the incidence of CMV reactivation and disease after autologous stem cell transplantation (ASCT), identify risk factors with particular focus on erythrocyte transfusion burden and immunomodulatory drug (IMID) exposure, and determine high-risk subgroups warranting intensified surveillance.
Methods
Retrospective analysis of 188 CMV-seropositive ASCT recipients at Erciyes University between 2007–2016. CMV PCR was performed twice weekly for the first 100 days. Erythrocyte suspension (ES) and platelet suspension (PS) were analysed separately alongside combined transfusion burden. Fisher exact and chi-square tests were used (SPSS v16.0).
Results
CMV reactivation occurred in 44 patients (23.4%); 40 (90.9%) had asymptomatic DNAemia and 4 (9.1%) developed CMV disease. All reactivation events occurred within day +46. Refractory/progressive disease was associated with higher reactivation rates (50.0% vs 21.9%; p=0.056). ES ?6 units was strongly associated with CMV reactivation (62.5% vs 24.0%; odds ratio [OR] 5.28, 95% confidence interval [CI]: 1.20–23.18; p=0.028), while PS alone was not (p=0.429). IMID exposure was significantly protective in multiple myeloma (MM) patients (9.5% vs 27.4%; p=0.022) and the overall cohort (9.3% vs 27.6%; p=0.013). The protective effect was independent of IMID timing (pre-transplant 10.5% vs post-transplant 9.5%; p=1.000). Conditioning regimen was not associated with CMV reactivation (p=0.863).
Conclusion
Refractory disease and high erythrocyte transfusion burden are the strongest predictors of CMV reactivation after ASCT. ES is the primary transfusion-related determinant. The timing-independent protective effect of IMIDs suggests a durable NK-cell mediated immunological mechanism. Risk-stratified CMV monitoring is recommended for high-risk subgroups.
Zitieren
APA
Ilgaz, M., Gökahmetoğlu, S., Çelik, M., & Kaynar, L. (2026). CMV reactivation after autologous stem cell transplantation: exploratory associations with transfusion burden and pre-transplant IMID exposure. Journal of Current Hematology & Oncology Research, 4(4), 135-139. https://doi.org/10.51271/jchor-0097
Vancouver
Ilgaz M, Gökahmetoğlu S, Çelik M, Kaynar L. CMV reactivation after autologous stem cell transplantation: exploratory associations with transfusion burden and pre-transplant IMID exposure. Journal of Current Hematology & Oncology Research. 2026;4(4):135-139. doi:10.51271/jchor-0097
BibTeX
@article{Ilgaz2026,
author = {Ilgaz, Meral and Gökahmetoğlu, Selma and Çelik, Mehmet and Kaynar, Leylagül},
title = {CMV reactivation after autologous stem cell transplantation: exploratory associations with transfusion burden and pre-transplant IMID exposure},
journal = {Journal of Current Hematology & Oncology Research},
year = {2026},
volume = {4},
number = {4},
pages = {135--139},
doi = {10.51271/jchor-0097}
}
EUVIMED